Table 2 Subgroup analysis and the pooled RR for patients
Outcomes | No. of studies | Heterogeneity (I2), % | RR (95% CI) | p for heterogeneity |
|---|---|---|---|---|
OS | ||||
 Auto-allo vs only-allo | 2 | 0 | 1.28 (1.11, 1.49) | 0.435 |
 Auto-allo vs tandem auto | 6 | 79 | 0.91 (0.77, 1.06) | 0.000 |
 MA vs RIC | 4 | 38.8 | 1.14 (0.95, 1.36) | 0.179 |
 High-risk vs standard-risk | 5 | 0 | 0.83 (0.67, 1.03) | 0.599 |
 First-line vs salvage therapy | 4 | 42.6 | 1.42 (1.14, 1.78) | 0.156 |
PFS | ||||
 Auto-allo vs only-allo | 3 | 17.6 | 1.46 (1.19, 1.80) | 0.297 |
 Auto-allo vs tandem auto | 5 | 79.9 | 1.27 (0.84, 1.93) | 0.001 |
 MA vs RIC | 4 | 61.9 | 1.32 (0.95, 1.83) | 0.049 |
 High-risk vs standard-risk | 5 | 6.1 | 0.89 (0.66, 1.20) | 0.372 |
 First-line vs salvage therapy | 4 | 0 | 2.80 (1.97, 3.97) | 0.948 |
TRM | ||||
 Auto-allo vs only-allo | 2 | 0 | 0.41 (0.27, 0.61) | 0.420 |
 Auto-allo vs tandem auto | 3 | 0 | 6.09 (2.92, 12.7) | 0.999 |
 MA vs RIC | 4 | 26.0 | 1.48 (1.14, 1.92) | 0.256 |
RR | ||||
 Auto-allo vs only-allo | 3 | 75.9 | 0.80 (0.51, 1.24) | 0.016 |
 Auto-allo vs tandem auto | 2 | 48.1 | 0.63 (0.50, 0.78) | 0.165 |
 MA vs RIC | 3 | 65.6 | 0.64 (0.43, 0.95) | 0.055 |